How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Sell
19
SOLV Quote, Financials, Valuation and Earnings
Last price:
$64.93
Seasonality move
:
-21.84%
Day range:
$64.04 - $65.39
52-week range:
$47.16 - $85.92
Dividend yield:
0%
P/E ratio:
23.25x
P/S ratio:
1.35x
P/B ratio:
3.74x
Volume:
786.4K
Avg. volume:
1.4M
1-year change:
2.8%
Market cap:
$11.1B
Revenue:
$8.3B
EPS (TTM):
$2.75
Analysts' Opinion
-
Consensus RatingSolventum has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $80.89, Solventum has an estimated upside of 26.51% from its current price of $63.94.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $71.00 representing 100% downside risk from its current price of $63.94.
Fair Value
-
According to the consensus of 10 analysts, Solventum has 26.51% upside to fair value with a price target of $80.89 per share.
SOLV vs. S&P 500
-
Over the past 5 trading days, Solventum has underperformed the S&P 500 by -1.2% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Solventum does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Solventum has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Solventum reported revenues of $2.1B.
Earnings Growth
-
Solventum earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Solventum reported earnings per share of $0.17.
Enterprise value:
18.3B
EV / Invested capital:
--
Price / LTM sales:
1.35x
EV / EBIT:
18.84x
EV / Revenue:
2.22x
PEG ratio (5yr expected):
--
EV / Free cash flow:
22.74x
Price / Operating cash flow:
13.79x
Enterprise value / EBITDA:
11.99x
Gross Profit (TTM):
$4.6B
Return On Assets:
3.31%
Net Income Margin (TTM):
5.8%
Return On Equity:
9.76%
Return On Invested Capital:
4.18%
Operating Margin:
6.55%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $8.2B | $8.3B | $2B | $2.1B | |
| Gross Profit | -- | $4.7B | $4.6B | $1.2B | $1.1B | |
| Operating Income | -- | $1.7B | $1B | $406M | $136M | |
| EBITDA | -- | $2.2B | $1.5B | $530M | $270M | |
| Diluted EPS | -- | $7.80 | $2.75 | $1.57 | $0.17 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $2.2B | $2.5B | $3.2B | |
| Total Assets | -- | -- | $13.6B | $13.9B | $14.5B | |
| Current Liabilities | -- | -- | $1.3B | $1.7B | $2.7B | |
| Total Liabilities | -- | -- | $1.9B | $2.3B | $11.5B | |
| Total Equity | -- | -- | $11.7B | $11.7B | $3B | |
| Total Debt | -- | -- | -- | -- | $8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $1.9B | $1.2B | $547M | $219M | |
| Cash From Investing | -- | -$230M | -$380M | -$88M | -$127M | |
| Cash From Financing | -- | -$1.6B | -$240M | -$306M | -$104M | |
| Free Cash Flow | -- | $1.6B | $805M | $459M | $92M | |
SOLV
Sector
Market Cap
$11.1B
$34.2M
Price % of 52-Week High
74.42%
42.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
2.8%
-41.76%
Beta (5-Year)
--
0.737
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$66.19
200-day SMA
Sell
Level
$68.21
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$69.84
Relative Strength Index (RSI14)
Sell
Level
39.36
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-80.9971
50-day SMA
Sell
Level
$73.67
MACD (12, 26)
Sell
Level
-2.66
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4572)
Buy
CA Score
(Annual)
Level (0.1401)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (2.0467)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.
Stock Forecast FAQ
In the current month, SOLV has received 1 Buy ratings 9 Hold ratings, and 0 Sell ratings. The SOLV average analyst price target in the past 3 months is $80.89.
-
Where Will Solventum Stock Be In 1 Year?
According to analysts, the consensus estimate is that Solventum share price will rise to $80.89 per share over the next 12 months.
-
What Do Analysts Say About Solventum?
Analysts are divided on their view about Solventum share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Solventum is a Sell and believe this share price will drop from its current level to $71.00.
-
What Is Solventum's Price Target?
The price target for Solventum over the next 1-year time period is forecast to be $80.89 according to 10 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is SOLV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Solventum is a Hold. 9 of 10 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SOLV?
You can purchase shares of Solventum via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Solventum shares.
-
What Is The Solventum Share Price Today?
Solventum was last trading at $64.93 per share. This represents the most recent stock quote for Solventum. Yesterday, Solventum closed at $63.94 per share.
-
How To Buy Solventum Stock Online?
In order to purchase Solventum stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Rocket Lab Vs Intuitive Machines Stock
The commercialization of outer space is now in full swing,…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
40
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 33x
Alerts
Buy
58
AGX alert for Apr 23
Argan [AGX] is up 3.08% over the past day.
Sell
44
INOD alert for Apr 22
Innodata [INOD] is up 5.26% over the past day.
Sell
44
UHS alert for Apr 22
Universal Health Services [UHS] is up 2.73% over the past day.
